Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $43.1429.

Several analysts recently issued reports on ZBIO shares. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Morgan Stanley lowered shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $37.00 to $19.00 in a research report on Monday, January 5th. Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th.

View Our Latest Research Report on ZBIO

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $20.16 on Friday. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $44.60. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -2.85 and a beta of -1.45. The company has a 50-day simple moving average of $33.87 and a 200 day simple moving average of $24.39. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. acquired 20,000 shares of the stock in a transaction on Friday, January 9th. The shares were purchased at an average price of $16.55 per share, for a total transaction of $331,000.00. Following the purchase, the chief executive officer directly owned 366,155 shares in the company, valued at approximately $6,059,865.25. The trade was a 5.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders purchased a total of 100,000 shares of company stock worth $1,639,000 over the last 90 days. Corporate insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Quarry LP raised its stake in Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Zenas BioPharma by 3.9% during the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock worth $452,000 after acquiring an additional 765 shares during the period. Bank of America Corp DE boosted its position in shares of Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after acquiring an additional 818 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Zenas BioPharma in the third quarter valued at approximately $30,000. Finally, Rhumbline Advisers raised its position in Zenas BioPharma by 7.6% during the third quarter. Rhumbline Advisers now owns 21,214 shares of the company’s stock valued at $471,000 after purchasing an additional 1,493 shares in the last quarter.

Zenas BioPharma Company Profile

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.

Read More